Creative Newtech Limited (NSE:CREATIVE)
India · Delayed Price · Currency is INR 618.00
-10.05 (-1.60%)
Aug 14, 2025, 3:30 PM IST
Achilles Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 18,667 | 17,748 | 17,206 | 13,928 | 9,470 | 5,201 | Upgrade |
Other Revenue | -3.25 | - | - | - | - | - | Upgrade |
Revenue | 18,664 | 17,748 | 17,206 | 13,928 | 9,470 | 5,201 | Upgrade |
Revenue Growth (YoY) | 20.20% | 3.15% | 23.54% | 47.06% | 82.07% | 13.64% | Upgrade |
Cost of Revenue | 840.27 | - | 15,992 | 12,962 | 8,566 | 4,751 | Upgrade |
Gross Profit | 17,824 | 17,748 | 1,214 | 966.02 | 904.16 | 450.22 | Upgrade |
Selling, General & Admin | -4.62 | - | 212.78 | 194.84 | 180.39 | 114.6 | Upgrade |
Other Operating Expenses | 17,188 | 17,132 | 511.68 | 414.99 | 396.88 | 147.24 | Upgrade |
Operating Expenses | 17,183 | 17,132 | 737.73 | 625.49 | 592.16 | 272.09 | Upgrade |
Operating Income | 640.36 | 615.45 | 476.02 | 340.53 | 312 | 178.13 | Upgrade |
Interest Expense | -15.6 | - | -72.5 | -75.94 | -45.03 | -34.06 | Upgrade |
Interest & Investment Income | - | - | 6.03 | 3.15 | 2.25 | 2.33 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 87.66 | 89.73 | -8.38 | -3.38 | Upgrade |
Other Non Operating Income (Expenses) | 0.7 | - | 85.04 | -16 | -11.8 | -12.91 | Upgrade |
EBT Excluding Unusual Items | 625.45 | 615.45 | 582.25 | 341.47 | 249.05 | 130.11 | Upgrade |
Other Unusual Items | - | - | - | - | -1.26 | - | Upgrade |
Pretax Income | 625.45 | 615.45 | 582.25 | 341.47 | 249.32 | 130.18 | Upgrade |
Income Tax Expense | 83.82 | 84.79 | 99.74 | 68.98 | 56.83 | 36.36 | Upgrade |
Earnings From Continuing Operations | 541.63 | 530.66 | 482.51 | 272.49 | 192.49 | 93.82 | Upgrade |
Minority Interest in Earnings | -2.61 | - | -41.89 | -26.55 | -32.64 | 1.68 | Upgrade |
Net Income | 539.03 | 530.66 | 440.62 | 245.94 | 159.86 | 95.5 | Upgrade |
Net Income to Common | 539.03 | 530.66 | 440.62 | 245.94 | 159.86 | 95.5 | Upgrade |
Net Income Growth | 4.75% | 20.44% | 79.16% | 53.85% | 67.38% | 22.81% | Upgrade |
Shares Outstanding (Basic) | 17 | 16 | 14 | 13 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 17 | 16 | 14 | 13 | 12 | 12 | Upgrade |
Shares Change (YoY) | 8.13% | 19.23% | 9.76% | 1.55% | 6.96% | - | Upgrade |
EPS (Basic) | 32.24 | 32.18 | 32.59 | 19.52 | 13.32 | 8.23 | Upgrade |
EPS (Diluted) | 32.24 | 32.18 | 31.86 | 19.52 | 12.88 | 8.23 | Upgrade |
EPS Growth | -3.13% | 1.01% | 63.22% | 51.54% | 56.50% | 22.77% | Upgrade |
Free Cash Flow | - | - | -287.12 | -219.52 | -209.19 | -61.55 | Upgrade |
Free Cash Flow Per Share | - | - | -20.76 | -17.42 | -16.86 | -5.31 | Upgrade |
Dividend Per Share | - | - | 0.500 | 0.500 | 0.500 | 0.500 | Upgrade |
Gross Margin | 95.50% | 100.00% | 7.05% | 6.94% | 9.55% | 8.66% | Upgrade |
Operating Margin | 3.43% | 3.47% | 2.77% | 2.44% | 3.29% | 3.43% | Upgrade |
Profit Margin | 2.89% | 2.99% | 2.56% | 1.77% | 1.69% | 1.84% | Upgrade |
Free Cash Flow Margin | - | - | -1.67% | -1.58% | -2.21% | -1.18% | Upgrade |
EBITDA | 653.03 | 628.29 | 488.86 | 355.74 | 326.46 | 187.95 | Upgrade |
EBITDA Margin | 3.50% | 3.54% | 2.84% | 2.55% | 3.45% | 3.61% | Upgrade |
D&A For EBITDA | 12.67 | 12.84 | 12.84 | 15.21 | 14.46 | 9.81 | Upgrade |
EBIT | 640.36 | 615.45 | 476.02 | 340.53 | 312 | 178.13 | Upgrade |
EBIT Margin | 3.43% | 3.47% | 2.77% | 2.44% | 3.29% | 3.43% | Upgrade |
Effective Tax Rate | 13.40% | 13.78% | 17.13% | 20.20% | 22.79% | 27.93% | Upgrade |
Revenue as Reported | 917 | - | 17,409 | 14,023 | 9,478 | 5,263 | Upgrade |
Advertising Expenses | - | - | 55.67 | 57.8 | 65.67 | 28.65 | Upgrade |
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.